Cargando…

Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells

The combination of histone deacetylase inhibitor and BRAF inhibitor (BRAFi) has been shown to enhance the antineoplastic effect and reduce the progress of BRAFi resistance. In this study, a series of (thiazol-5-yl)pyrimidin-2-yl)amino)-N-hydroxyalkanamide derivatives were designed and synthesized as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yingjun, Huang, Yongjun, Cheng, Huimin, Xu, Fang, Qi, Ruxi, Dai, Botao, Yang, Yujian, Tu, Zhengchao, Peng, Lijie, Zhang, Zhang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354042/ https://www.ncbi.nlm.nih.gov/pubmed/35936102 http://dx.doi.org/10.3389/fchem.2022.910353

Ejemplares similares

Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment
por: Zhou, Maojun, et al.
Publicado: (2021)

MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF
por: Wang, Zhenlei, et al.
Publicado: (2015)

AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
por: Ma, Rui, et al.
Publicado: (2018)

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations
por: Lu, Meng-Di, et al.
Publicado: (2022)

MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer
por: Mao, Q.D., et al.
Publicado: (2017)

Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents
por: Liang, Sudong, et al.
Publicado: (2023)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells
por: Liu, Jiaqi, et al.
Publicado: (2016)

Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line
por: Kusaczuk, Magdalena, et al.
Publicado: (2015)

HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human γδT Cells
por: He, Ying, et al.
Publicado: (2020)

Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
por: Zhao, Qian, et al.
Publicado: (2022)

Histone deacetylase (HDAC) 11 inhibits matrix metalloproteinase (MMP) 3 expression to suppress colorectal cancer metastasis
por: Wen, Yuqing, et al.
Publicado: (2022)

RANBP9 suppresses tumor proliferation in colorectal cancer
por: Qin, Chunzhi, et al.
Publicado: (2019)

Targeting mutant BRAF in colorectal cancer
por: Carroll, David, et al.
Publicado: (2013)

BRAF Mutation in Colorectal Cancer: An Update
por: Barras, David
Publicado: (2015)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2015)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
por: Celesia, Adriana, et al.
Publicado: (2023)

Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells
por: Li, Jing, et al.
Publicado: (2017)

GPR126 regulates colorectal cancer cell proliferation by mediating HDAC2 and GLI2 expression
por: Cui, Hengxiang, et al.
Publicado: (2021)

Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
por: Zhao, Qian, et al.
Publicado: (2023)

Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy
por: Mazor, Roei D, et al.
Publicado: (2020)

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
por: Sinatra, Laura, et al.
Publicado: (2020)

Discovery of New Uracil and Thiouracil Derivatives as Potential HDAC Inhibitors
por: Elbatrawy, Omnia R., et al.
Publicado: (2023)

Discovery of deoxyandrographolide and its novel effect on vascular senescence by targeting HDAC1
por: Lin, Zhongxiao, et al.
Publicado: (2023)

Synaptotagmin7 Is Overexpressed In Colorectal Cancer And Regulates Colorectal Cancer Cell Proliferation
por: Wang, Kewei, et al.
Publicado: (2018)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells
por: Lamichhane, Astha, et al.
Publicado: (2023)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

The implication of BRAF mutation in advanced colorectal cancer
por: O’Riordan, Emma, et al.
Publicado: (2021)

Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway
por: Ye, Geni, et al.
Publicado: (2023)

The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors
por: Zhang, Xuan, et al.
Publicado: (2013)

The Genomic Environment of BRAF Mutated and BRAF/PIK3CA Double Mutated Colorectal Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Natural chalcones as dual inhibitors of HDACs and NF-κB
por: ORLIKOVA, B., et al.
Publicado: (2012)

Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer
por: Roy, Rubi, et al.
Publicado: (2023)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

Potential clinical implications of BRAF mutations in histiocytic proliferations
por: Bubolz, Anna-Maria, et al.
Publicado: (2014)

Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis
por: Zhang, Wentian, et al.
Publicado: (2020)

Complete response with fluorouracil and irinotecan with a BRAF(V600E) and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report
por: Wang, Zhan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j650389rps1e3qsdmv0t363orj